WDCP

Summary

WDCP (WD repeat and coiled coil containing, HGNC:26157) is a protein-coding gene on chromosome 2p23.3, encoding WD repeat and coiled-coil-containing protein (Q9H6R7).

Enables kinase binding activity. Involved in protein complex oligomerization.

Source: NCBI Gene 80304 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 3 total
• MANE Select transcript: NM_025203

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26157
Approved symbol	WDCP
Name	WD repeat and coiled coil containing
Location	2p23.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ21945, MMAP
Ensembl gene	ENSG00000163026
Ensembl biotype	protein_coding
OMIM	616234
Entrez	80304

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000295148, ENST00000406895, ENST00000443232

RefSeq mRNA: 2 — MANE Select: NM_025203 NM_001142319, NM_025203

CCDS: CCDS1705, CCDS46229

Canonical transcript exons

ENST00000295148 — 4 exons

Exon	Start	End
ENSE00001070762	24032829	24032946
ENSE00001135617	24037677	24039512
ENSE00001904600	24047314	24047391
ENSE00001944632	24029347	24031162

Expression profiles

Bgee: expression breadth ubiquitous, 186 present calls, max score 88.79.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.3976 / max 211.4608, expressed in 1633 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
27300	6.6348	1607
27299	0.7628	446

Top tissues by expression

272 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	88.79	gold quality
cortical plate	UBERON:0005343	83.28	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.24	gold quality
ganglionic eminence	UBERON:0004023	80.86	gold quality
ventricular zone	UBERON:0003053	80.57	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.06	gold quality
stromal cell of endometrium	CL:0002255	78.56	gold quality
embryo	UBERON:0000922	77.69	gold quality
oocyte	CL:0000023	77.48	gold quality
gastrocnemius	UBERON:0001388	77.38	gold quality
muscle of leg	UBERON:0001383	77.14	gold quality
adrenal tissue	UBERON:0018303	76.61	gold quality
hindlimb stylopod muscle	UBERON:0004252	76.42	gold quality
pancreatic ductal cell	CL:0002079	75.77	silver quality
colonic epithelium	UBERON:0000397	75.20	gold quality
islet of Langerhans	UBERON:0000006	75.10	gold quality
right coronary artery	UBERON:0001625	74.22	gold quality
right adrenal gland	UBERON:0001233	73.84	gold quality
granulocyte	CL:0000094	73.75	gold quality
descending thoracic aorta	UBERON:0002345	73.69	gold quality
lower esophagus muscularis layer	UBERON:0035833	73.31	gold quality
lower esophagus	UBERON:0013473	73.29	gold quality
tendon of biceps brachii	UBERON:0008188	73.18	silver quality
lymph node	UBERON:0000029	73.15	gold quality
right adrenal gland cortex	UBERON:0035827	73.15	gold quality
calcaneal tendon	UBERON:0003701	73.10	gold quality
muscle layer of sigmoid colon	UBERON:0035805	73.10	gold quality
tendon	UBERON:0000043	73.08	gold quality
left adrenal gland	UBERON:0001234	72.86	gold quality
left coronary artery	UBERON:0001626	72.70	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.96

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

60 targeting WDCP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-8062	99.88	68.43	995
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-132-3P	99.73	70.56	1424
HSA-MIR-212-3P	99.73	70.65	1424
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-6848-3P	99.64	66.49	885
HSA-MIR-9851-3P	99.63	69.68	1110
HSA-MIR-3609	99.52	69.89	2587
HSA-MIR-548AH-5P	99.52	69.73	2626
HSA-MIR-642A-5P	99.51	65.10	1152
HSA-MIR-548G-3P	99.48	68.67	2159
HSA-MIR-1324	99.46	66.57	1302
HSA-MIR-6080	99.43	69.43	373
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-4786-3P	99.36	68.35	1390

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	wdcp	ENSDARG00000016528
mus_musculus	Wdcp	ENSMUSG00000051721
rattus_norvegicus	Wdcp	ENSRNOG00000049989

Protein

Protein identifiers

WD repeat and coiled-coil-containing protein — Q9H6R7 (reviewed: Q9H6R7)

All UniProt accessions (2): C9JYC1, Q9H6R7

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Oligomer. Interacts with HCK (via SH3 domain).

Post-translational modifications. Phosphorylated on Tyr when associated with HCK.

Disease relevance. A chromosomal aberration involving WDCP is found in one subject with colorectal cancer. Translocation t(2;2)(p23.3;p23.1). A 5 million base pair tandem duplication generates an in-frame WDCP-ALK gene fusion.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9H6R7-1	1	yes
Q9H6R7-2	2
Q9H6R7-3	3

RefSeq proteins (2): NP_001135791, NP_079479* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR028041	WDCP	Family

Pfam: PF15390

UniProt features (23 total): modified residue 8, splice variant 4, repeat 2, sequence variant 2, mutagenesis site 2, region of interest 2, chain 1, coiled-coil region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H6R7-F1	68.33	0.32

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 501, 523, 530, 686, 690, 1, 299, 468

Mutagenesis-validated functional residues (2):

Position	Phenotype
540	loss of interaction with hck; when associated with p-543.
543	loss of interaction with hck; when associated with p-543.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9725370	Signaling by ALK fusions and activated point mutants

MSigDB gene sets: 74 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_UP, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, ACEVEDO_LIVER_CANCER_UP, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, GEORGES_TARGETS_OF_MIR192_AND_MIR215, GOMF_KINASE_BINDING, GSE13762_CTRL_VS_125_VITAMIND_DAY5_DC_DN, MIKKELSEN_ES_ICP_WITH_H3K4ME3, MIKKELSEN_NPC_ICP_WITH_H3K4ME3, GOBP_PROTEIN_COMPLEX_OLIGOMERIZATION, TAYLOR_METHYLATED_IN_ACUTE_LYMPHOBLASTIC_LEUKEMIA, MODULE_426, REACTOME_DISEASES_OF_SIGNAL_TRANSDUCTION_BY_GROWTH_FACTOR_RECEPTORS_AND_SECOND_MESSENGERS, ASH1L_TARGET_GENES, BARX1_TARGET_GENES

GO Biological Process (1): protein complex oligomerization (GO:0051259)

GO Molecular Function (2): kinase binding (GO:0019900), protein binding (GO:0005515)

GO Cellular Component (0):

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by ALK in cancer	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein-containing complex assembly	1
enzyme binding	1
binding	1

Protein interactions and networks

STRING

594 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WDCP	ALK	Q9UM73	639
WDCP	EML4	Q9HC35	505
WDCP	HAUS6	Q7Z4H7	493
WDCP	KIF5B	P33176	479
WDCP	ZNHIT2	Q9UHR6	463
WDCP	PPP1R21	Q6ZMI0	418
WDCP	TNIP1	Q15025	418
WDCP	ITSN1	Q15811	414
WDCP	OGA	O60502	393
WDCP	CYLD	Q9NQC7	379
WDCP	TBK1	Q9UHD2	370
WDCP	STRN	O43815	369
WDCP	EFCAB8	A8MWE9	369
WDCP	KLC1	Q07866	352
WDCP	NOPCHAP1	Q8N5I9	352

IntAct

126 interactions, top by confidence:

A	B	Type	Score
ANKRD40	AHCY	psi-mi:“MI:0914”(association)	0.900
RUVBL1	ZNHIT1	psi-mi:“MI:0914”(association)	0.860
CTBP1	ZEB2	psi-mi:“MI:0914”(association)	0.800
RNF146	TNKS	psi-mi:“MI:0914”(association)	0.790
CTBP1	CBX4	psi-mi:“MI:0914”(association)	0.700
IFT27	IFT56	psi-mi:“MI:0914”(association)	0.690
HIF1AN	GMDS	psi-mi:“MI:0914”(association)	0.640
RUVBL2	POLR3A	psi-mi:“MI:0914”(association)	0.640
RUVBL1	POLR3A	psi-mi:“MI:0914”(association)	0.640
PLK1	C1orf226	psi-mi:“MI:0914”(association)	0.560
EMILIN1	METTL15	psi-mi:“MI:0914”(association)	0.530
FKBP6	EEF2K	psi-mi:“MI:0914”(association)	0.530
WDCP	PAPSS1	psi-mi:“MI:0914”(association)	0.530
GNA15	HSPA8	psi-mi:“MI:0914”(association)	0.530
PICK1	ILVBL	psi-mi:“MI:0914”(association)	0.530
INSYN2A	CHUK	psi-mi:“MI:0914”(association)	0.530
ZNF408	LRP4	psi-mi:“MI:0914”(association)	0.530

BioGRID (152): C2orf44 (Affinity Capture-MS), C2orf44 (Affinity Capture-MS), C2orf44 (Affinity Capture-MS), C2orf44 (Affinity Capture-MS), C2orf44 (Affinity Capture-MS), C2orf44 (Proximity Label-MS), C2orf44 (Proximity Label-MS), C2orf44 (Proximity Label-MS), C2orf44 (Affinity Capture-MS), C2orf44 (Affinity Capture-MS), C2orf44 (Affinity Capture-MS), C2orf44 (Affinity Capture-MS), C2orf44 (Affinity Capture-MS), C2orf44 (Affinity Capture-MS), C2orf44 (Affinity Capture-MS)

ESM2 similar proteins: A0A1L8GXY4, A0A1L8I2C5, A1A5R7, A6PWY4, A9X1C6, B1ANS9, B2KIQ4, D3Z3I0, E9Q7R9, F1QHZ6, O13286, O74845, O94411, P26309, P43254, P51956, P93471, Q09786, Q4V837, Q5R6T6, Q5TKR9, Q5XHI9, Q5ZKI7, Q6DTM3, Q6GM71, Q6GPU3, Q6VZ17, Q7Z2W4, Q80Z32, Q86VD1, Q86Y33, Q8BZ21, Q8CDP0, Q8K3E5, Q8L4H0, Q8N157, Q8N4N8, Q8NA75, Q8NDM7, Q8NEM8

Diamond homologs: Q08D12, Q5RFV8, Q5ZKI7, Q6DDJ5, Q6NV72, Q9H6R7

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
PLK1	“up-regulates activity”	WDCP	phosphorylation
WDCP	“up-regulates activity”	KIF2A	binding
WDCP	“up-regulates activity”	MRE11	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 152 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of canonical Wnt signaling pathway	9	10.2×	3e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

3 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

456 predictions. Top by Δscore:

Variant	Effect	Δscore
2:24031163:C:CC	acceptor_gain	1.0000
2:24031159:GAATC:G	acceptor_loss	0.9900
2:24031160:AATC:A	acceptor_loss	0.9900
2:24031162:TC:T	acceptor_loss	0.9900
2:24031163:C:G	acceptor_loss	0.9900
2:24031164:T:A	acceptor_loss	0.9900
2:24032947:C:CC	acceptor_gain	0.9900
2:24039509:TTAC:T	acceptor_gain	0.9900
2:24039510:TAC:T	acceptor_gain	0.9900
2:24039513:C:CC	acceptor_gain	0.9900
2:24039513:CTG:C	acceptor_loss	0.9900
2:24039514:T:C	acceptor_loss	0.9900
2:24031169:A:AC	acceptor_gain	0.9800
2:24032879:AG:A	donor_gain	0.9800
2:24032942:GGTTT:G	acceptor_gain	0.9800
2:24032945:TT:T	acceptor_gain	0.9800
2:24032946:TCT:T	acceptor_loss	0.9800
2:24032947:C:A	acceptor_loss	0.9800
2:24032948:T:A	acceptor_loss	0.9800
2:24039508:GTTAC:G	acceptor_gain	0.9800
2:24039518:A:AC	acceptor_gain	0.9800
2:24031158:GGAAT:G	acceptor_gain	0.9700
2:24031159:GAAT:G	acceptor_gain	0.9700
2:24031161:AT:A	acceptor_gain	0.9700
2:24031169:A:C	acceptor_gain	0.9700
2:24032944:TTT:T	acceptor_gain	0.9700
2:24039511:AC:A	acceptor_gain	0.9700
2:24039512:CC:C	acceptor_gain	0.9700
2:24039522:T:C	acceptor_gain	0.9700
2:24047309:AATAC:A	donor_loss	0.9700

AlphaMissense

4715 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:24039134:A:G	W121R	0.991
2:24039134:A:T	W121R	0.991
2:24039005:A:G	W164R	0.990
2:24039005:A:T	W164R	0.990
2:24039003:C:A	W164C	0.986
2:24039003:C:G	W164C	0.986
2:24039413:A:G	W28R	0.986
2:24039413:A:T	W28R	0.986
2:24039132:C:A	W121C	0.984
2:24039132:C:G	W121C	0.984
2:24039302:A:G	W65R	0.983
2:24039302:A:T	W65R	0.983
2:24038426:C:G	A357P	0.982
2:24038327:C:G	G390R	0.981
2:24038327:C:T	G390R	0.981
2:24031084:A:T	I672K	0.979
2:24038327:C:A	G390W	0.977
2:24038464:A:G	L344P	0.977
2:24032870:A:T	V632D	0.975
2:24037693:A:T	V601D	0.974
2:24031122:A:C	F659L	0.973
2:24031122:A:T	F659L	0.973
2:24031124:A:G	F659L	0.973
2:24031144:A:T	L652H	0.973
2:24031154:A:G	W649R	0.973
2:24031154:A:T	W649R	0.973
2:24038432:C:G	A355P	0.973
2:24038983:A:G	L171P	0.972
2:24032857:A:C	F636L	0.968
2:24032857:A:T	F636L	0.968

dbSNP variants (sampled 300 via entrez): RS1000029386 (2:24036180 T>C), RS1000083777 (2:24043561 T>C), RS1000485936 (2:24035968 C>T), RS1001100524 (2:24042754 C>G,T), RS1001182352 (2:24049215 G>T), RS1001250807 (2:24042205 C>G), RS1001482219 (2:24040010 A>C,T), RS1001645645 (2:24047384 G>T), RS1001764178 (2:24042591 C>A,T), RS1001817843 (2:24041579 C>A), RS1001944955 (2:24030515 C>T), RS1002029969 (2:24048490 A>G,T), RS1002099457 (2:24047275 C>T), RS1002427313 (2:24048857 C>T), RS1002436023 (2:24041982 T>A)

Disease associations

OMIM: gene MIM:616234 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST000337_33	Quantitative traits	6.000000e-06
GCST006945_26	Feeling guilty	6.000000e-14

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004458	C-reactive protein measurement
EFO:0009595	guilt measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
bisphenol A	affects cotreatment, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
resorcinol	increases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
2-palmitoylglycerol	increases expression	1
K 7174	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	increases expression, decreases reaction	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Air Pollutants	affects cotreatment, decreases expression, increases abundance	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Vehicle Emissions	decreases reaction, increases expression	1
Caffeine	decreases phosphorylation	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Indomethacin	affects cotreatment, increases expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Ozone	decreases expression, increases abundance, affects cotreatment	1
Thiram	decreases expression	1
Tretinoin	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.